Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 8, Issue , 2007, Pages

  Alexiou, Ioannis ^a   Germenis, Anastasios ^a   Ziogas, Athanasios ^a   Theodoridou, Katerina ^a   Sakkas, Lazaros I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DR ANTIGEN; RHEUMATOID FACTOR; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; RANK SUM TEST; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SWELLING; AGED; BLOOD; COMPARATIVE STUDY; GREECE; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC;

EID: 34249110605     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-8-37     Document Type: Article

References (27)

1. Guidelines for the management of rheumatoid arthritis. ACR subcommittee on RA Guidelines, Arthritis Rheum 2002 46 328 46 10.1002/art.10148 11840435
2. Autoantibodies in rheumatoid arthritis and their clinical significance. G Steiner J Smolen, Arthritis Res 2002 4 suppl 2 S1 S5 10.1186/ar551 12110150
3. Modifications of arginine and their role in autoimmunity. MA van Boekel WJ van Venrooij, Autoimmine Rev 2003 2 57 62 10.1016/S1568-9972(02)00128-3
4. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. GA Schellekens H Visser BAW de Jong FHJ van den Hoogen JMW Hazes FC Breedveld WJ van Venrooij, Arthritis Rheum 2000 43 155 63 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3 10643712
5. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. H Visser S le Cessie K Vos FC Breedveld JMW Hazes, Arthritis Rheum 2002 46 357 65 10.1002/art.10117 11840437
6. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. DM Lee PH Schur, Ann Rheum Dis 2003 62 870 74 10.1136/ard.62.9.870 12922961
7. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. K Suzuki T Sawada A Murakami T Matsui S Tohma K Nakazono M Takemura Y Takasaki T Mimori K Yamamoto, Scan J Rheumatol 2003 32 197 204 10.1080/03009740310003677
8. Evaluation of the anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatoid arthritis. S Dubucquoi E Solau-Gervais D Lefranc L Marguerie J Sibilia J Goetz V Dutoit A-L Fauchais E Hachulla R-M Flipo L Prin, Ann Rheum Dis 2004 63 415 19 15020336 10.1136/ard.2003.008623
9. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). A Kastbom G Strandberg A Lindroos T Skogh, Ann Rheum Dis 2004 63 1085 89 10.1136/ard.2003.016808 15308517
10. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. I Vallbracht J Rieber M Oppermann F Förger U Siebert K Helmke, Ann Rheum Dis 2004 63 1079 84 10.1136/ard.2003.019877 15308516
11. Use and significance of anti-CCP autoantibodies in rheumatoid arhritis. AJW Zendman WJ van Venrooij GJM Pruijn, Rheumatology 2006 45 20 25 10.1093/rheumatology/kei111 16188946
12. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis:diagnostic value, associations with radiological progression rate, and extra-articular manifestations. L De Rycke I Peene IEA Hoffman E Kruithof A Union L Meheus K Lebeer C Vincent H Mielants L Boullart G Serre EM Veys F de Keyser, Ann Rheum Dis 2004 63 1587 93 10.1136/ard.2003.017574 15547083
13. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). K Forslind M Ahlmén K Eberhardt I Hafström B Svensson for the BARFOT study group, Ann Rheum Dis 2004 63 1090 95 10.1136/ard.2003.014233 15308518
14. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. FA van Gaalen J van Aken TWJ Huizinga GMTH Schreuder FC Breedveld E Zanelli WJ van Venrooij CL Verweij REM Toes RRP de Vries, Arthritis Rheum 2004 50 2113 21 10.1002/art.20316 15248208
15. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. J Ronnelid MC Wick J Lampa S Lindblad B Nordmark L Klareskog RF van Vollenhoven, Ann Rheum Dis 2005 64 1744 49 10.1136/ard.2004.033571 15843452
16. HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients. KA Boki GS Panayi RW Vaughan AA Drosos HM Moutsopoulos JS Lanchbury, Arthritis Rheum 1992 35 749 55 10.1002/art.1780350706 1352449
17. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper LA Healey SR Kaplan MH Liang HS Luthra TA Medsger DM Mitchel DH Neustadt RS Pinals JG Schaller JT Sharp RL Wilder GG Hunder, Arthritis Rheum 1988 31 315 24 10.1002/art.1780310302 3358796
18. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. ML Prevoo MA van't Hof HH Kuper MA van Leeuwen LB van de Putte PL van Riel, Arthritis Rheum 1995 38 44 48 10.1002/art.1780380107 7818570
19. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies? A Larsen, J Rheumatol 1995 22 1974 75 8992003
20. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. A Larsen K Dale M Eek, Acta Radiol Diagn (Stockh) 1977 18 481 491 920239
21. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthtitis. FA Van Gaalen SP Linn-Rasker WJ van Venrooij BA de Jong FC Breedveld CL Verweij REM Toes TWJ Huizinga, Arthritis Rheum 2004 50 709 15 10.1002/art.20044 15022309
22. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. GA Schellekens BAW de Jong FHJ van den Hoogen LBA van de Putte, J Clin Invest 1998 101 273 81 9421490
23. Diagnostic accuracy of anti-citrulline antibody assay for rheumatoid arthritis. N Bizzaro G Mazzanti E Tonutti D Villalta R Tozzoli, Clinical Chemistry 2001 47 6 1089 93 11375296
24. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFa therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. C Alessandri M Bombardieri N Papa M Cinquini L Magrini A Tincani G Valestini, Ann Rheum Dis 2004 63 1218 21 10.1136/ard.2003.014647 15361374
25. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. E-JJA Kroot BAW de Jong MA van Leeuwen H Swinkels FHJ van den Hoogen M van't Hof LBA van de Putte MH van Rijswijk WJ van Venrooij PLCM van Riel, Arthritis Rheum 2000 43 1831 35 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6 10943873
26. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. E Berglin L Padyukov U Sundin G Hallmans H Stenlund WJ van Venrooij L Klareskog S Rantapaa-Dahlqvist, Arthritis Res Ther 2004 6 R303 R308 15225365 10.1186/ar1187
27. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. O Vittecoq B Incaurgarat F Jouen-Beades J Legoedec O Letourneur D Rolland G Gervasi JF Menard A Gayet P Fardellone A Daragon M Jolivet X Le Loet F Tron, Clin Exp Immunol 2004 135 173 80 10.1111/j.1365-2249.2004.02341.x 14678280